Floatz logo

xnw5004

Relapsed/Refractory Peripheral T Cell Lymphoma

Evopoint Biosciences Inc.Phase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

135 Active assets in the Relapsed/Refractory Peripheral T Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Pralatrexate
Peking University People's Hospital
Phase 4BBB
PREDNISONE TABLETS
Tarapeutics Science Inc.
Phase 4BBB
Inno-206
BeBetter Med Inc
Phase 4BBB
(+)-VINCRISTINE
BeBetter Med Inc
Phase 4BBB
Cyclophosphamide
Tarapeutics Science Inc.
Phase 4BBB

View all 50 →

Same molecule, other indications

xnw5004 is also rated in:

Follicular Lymphoma Grade 3ADormant
CCC
Indicative ·
53 / 100
View asset →
neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →
metastatic prostate carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →